nmin’s strategic initiative (si) program focuses on supporting just-in-time research development, commercialization and knowledge mobilization/transfer opportunities that arise in-year and/or require a rapid response in order to generate, promote or accelerate the economic and social benefits of previous or new nmin or related research investments. these funds are intended to provide support for research, post-discovery commercialization, business planning and knowledge dissemination, mobilization, or translation activities. the projects must be scaled to be achievable within a one-year/12-month timeframe and be aligned with nmin’s mission and vision. ideally, the si will be undertaken in partnership with nmin partners, stakeholders, and/or end-user organizations.

sshrc is launching a call for proposals in support of canadian researchers’ engagement with european research consortia funded via the horizon 2020 (h2020) research platform. this is the second round of this sshrc funding opportunity.

in october 2017, the european union (eu) launched h2020, a final three-year work program representing the largest eu research funding platform to date, comprising calls for research totalling €30 billion. in 2020, the last year of the work program, the platform includes an ambitious plan for international research collaboration on migration issues, with up to €32 million for topics ranging from the international protection of refugees to the integration of migrant children.

sshrc encourages interested canadian researchers to work directly with research teams from eu member states on the theme of migration within h2020 societal challenge 6: europe in a changing world—inclusive, innovative and reflective societies.

sshrc will make one- to three-year awards valued at $75,000 to $200,000 available to researchers (affiliated with an eligible canadian institution) on successful h2020 research teams.

description: fund research projects that will address important questions related to sensory disorders and their impact on the nervous system. they may include, among others, research into disorders of vision, hearing, and other sensory modalities, the somatosensory system, as well as multisensory dysfunction. research questions across modalities are encouraged, but focus on a single modality is also invited in the present call.

the voucher for innovation and productivity (vip) program helps companies develop, implement and commercialize technical innovations by supporting partnerships between ontario's industry and publicly funded post-secondary institutions. vip projects are intended to generate economic benefit for companies in ontario (including job creation/retention, new revenue generation, investment attraction, cost savings, value chain development), in the short-to-medium term (e.g. within three years of project completion).

the wsib is now accepting proposals for the 2020 grants program!

initial proposal deadline: friday, february 14, 2020

the wsib grants program aims to enhance workers’ compensation system outcomes by supporting innovative proposals that are aligned to the wsib's strategic mandate. the proposals funded through the program will help to strengthen ontario's workers' compensation system and deliver on our priority of making ontario a safer place to work.

grant priority areas

the central areas of focus for the 2020 wsib grants program support the wsib’s strategic plan to:

1)         make ontario a safer place to work

2)         improve return to work and recovery outcomes

3)         meet our customers’ needs and expectations

the grants program is committed to supporting the wsib’s strategic priority of being financially responsible and accountable through the operating practices of the program on an ongoing basis.

applicants are encouraged to submit proposals that align to the priority areas and topics of interest identified. highly practical research and training proposals are also accepted.

for more information about the program and the application process, please visit our website.

from: national research council canada

sectors: all industry sectors, all civilian markets.

open to:

• small and medium-sized enterprises (smes)
• large enterprises and industries
• universities
• research organizations
• others

next deadline: february 13, 2020

important: eurostars is delivered through the national research council. in order to be ready to submit a project proposal before the february 13, 2020 deadline, you must reach out to canada's eurostars national project coordinator, eric holdrinet. smes should also inform their nrc irap industrial technology advisor.

financial support: financial support may be provided to selected smes in canada which are eligible for nrc irap assistance. support for project partners varies according to funding eligibility in their respective countries.

note: consult the complete list of eurostars participating countries, which includes dozens of european countries, turkey, israel, south africa and south korea.

more information: eurostars program

the fy20 defense appropriation act is providing funding to the department of defense breast cancer research program (bcrp) to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for service members, veterans, and the general public.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

fy20 bcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.    

https://cdmrp.army.mil/funding/bcrp

applications submitted to the fy20 bcrp must address one or more of the following overarching challenges:

• prevent breast cancer (primary prevention)
• identify determinants of breast cancer initiation, risk, or susceptibility
• distinguish deadly from non-deadly breast cancers
• conquer the problems of overdiagnosis and overtreatment
• identify what drives breast cancer growth; determine how to stop it
• identify why some breast cancers become metastatic
• determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
• revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
• eliminate the mortality associated with metastatic breast cancer

breakthrough award levels 1 and 2 – letter of intent due march 12, 2020

independent investigators at all academic levels (or equivalent).

• applications from postdoctoral fellows are encouraged to apply under funding levels 1 and 2.
  • supports promising research that has high potential to lead to or make breakthroughs in breast cancer.
  • potential impact of the research may be near-term or long-term, but it must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development.
  • partnering pi option allows two principal investigators (pis), termed initiating and partnering pis, to collaborate on a single application.
  • different funding levels, based on the scope of research, are available for the breakthrough award.  it is the responsibility of the pi to select the funding level that is most appropriate for the research proposed.  the funding level should be selected based on the scope of the research project, rather than the amount of the budget.

the following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level:

• funding level 1:  innovative, high-risk/high-reward research that is in the earliest stages of idea development or an untested theory that addresses an important problem.  to foster research that yields new avenues of investigation, preliminary data are not required. proof-of-concept is the anticipated outcome.
  • funding level 2:  preclinical research that is already supported by substantial preliminary or published data and strongly validates clinical translation in a well-defined context within the breast cancer landscape.
  • funding level 2 – population science and prevention studies: preclinical research that is already supported by substantial preliminary or published data and strongly validates clinical translation in a well-defined context within the breast cancer landscape.  with compelling justification, population science and prevention studies may request higher levels of funding and an additional year in the period of performance. such studies may require additional resources due to the participation of human subjects and/or use of human biospecimens.

funding levels 1 and 2

• submission of a letter of intent is required prior to full application submission.
• each pi may submit only one application as a pi or initiating pi for each funding level.  there are no limitations on the number of applications for which an investigator may be named as a partnering pi.  however, applicants are discouraged from submitting as a partnering pi on multiple applications unless they are clearly unique, meaningful collaborations addressing distinct research questions.
• additional funds are available for applications submitted under the partnering pi option or the population science and prevention studies option.
• clinical trials are not allowed.

funding level 1

• maximum funding of $450,000 for direct costs (plus indirect costs)
• maximum period of performance is 3 years

funding level 1 – partnering pi option

• maximum funding of $750,000 for direct costs (plus indirect costs)
• maximum period of performance is 3 years

funding level 2

• maximum funding of $1 million (m) for direct costs (plus indirect costs)
• maximum period of performance is 3 years

funding level 2 – partnering pi option

• maximum funding of $1.5m for direct costs (plus indirect costs)
• maximum period of performance is 3 years

funding level 2 – population science and prevention studies

• maximum funding of $1.5m for direct costs (plus indirect costs)
• maximum period of performance is 4 years

funding level 2 – population science and prevention studies – partnering pi option

• maximum funding of $2m for direct costs (plus indirect costs)
• maximum period of performance is 4 years

breakthrough award level 3 – preproposal due march 13, 2020

independent investigators at all academic levels (or equivalent).

• supports promising research that has high potential to lead to or make breakthroughs in breast cancer.
• potential impact of the research may be near-term or long-term, but it must move beyond a minor advancement and have the potential to lead to a new approach or in clinical development.
• partnering pi option allows two pis, termed initiating and partnering pis, to collaborate on a single application.

different funding levels, based on the scope of research are available for the breakthrough award.  it is the responsibility of the pi to select the funding level that is most appropriate for the research proposed.  the funding level should be selected based on the scope of the research project, rather than the amount of the budget.

the following is a general description, although no all-inclusive, of the scope of research projects that would be appropriate under this funding level:

• funding level 3:  advanced translational studies with a high degree of project readiness. where relevant, proof of availability of and access to necessary data, human samples, cohort(s), and/or critical reagents must be provided. if the proposed research would ultimately require us food and drug administration (fda) involvement, applications must demonstrate availability of and access to clinical reagents (e.g., therapeutic molecules) and subject population(s). applications must state a realistic timeline for near-term clinical investigation. small-scale clinical trials (e.g., first in human; phase i/ib) may be appropriate.

additional elements

• submission of a preproposal is required; application submission is by invitation only.
• there are no limits on the number of pre-applications for which an investigator may be named pi, initiating pi, or partnering pi. investigators are discouraged from being named on multiple pre-applications unless they clearly addressing distinct research questions.
• additional funds are available for funding level 3 applications submitted under the partnering pi option.
• applications must include two or more breast cancer advocates on their research team.
• clinical trials are allowed.

funding level 3

• maximum funding of $3m in direct costs (plus indirect costs)
• maximum period of performance is 4 years

funding level 3 with partnering pi option

• maximum funding of $4m for direct costs (plus indirect costs)
• maximum period of performance is 4 years

breakthrough award level 4 – preproposal due march 13, 2020

independent investigator at all academic levels (or equivalent)

• supports promising research that has high potential to lead to or make breakthroughs in breast cancer.
• potential impact of the research may be near-term or long-term, but it must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development.
• partnering pi option allows two pis, termed initiating and partnering pis, to collaborate on a single application.

different funding levels, based on the scope of research are available for the breakthrough award.  it is the responsibility of the pi to select the funding level that is most appropriate for the research proposed.  the funding level should be selected based on the scope of the research project, rather than the amount of the budget.

the following is a general description, although no all-inclusive, of the scope of research projects that would be appropriate under this funding level:

funding level 4: large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer.  human clinical trials are required.  pis are expected to have experience in successfully leading large-scale projects and demonstrated ability (through personal experience or via a commitment from a collaboration clinical investigator) to implement a clinical project successfully.  where relevant applications must demonstrate availability of and access to necessary data, human samples, cohort(s), and/or critical reagents.  for proposed research that will require fda involvement, project readiness requirements at the time of application submission include: proof of availability of and access to clinical reagents (e.g., therapeutics) that meet regulatory compliance guidelines; proof of availability and access to appropriate subject population(s); validated projections for patient recruitment; and submission of an investigational new drug (ind) or investigational device exemption (ide) application to the fda, if applicable.

additional elements

• submission of a preproposal is required; application submission is by invitation only.
• there are no limits on the number of pre-applications for which an investigator may be named as a pi, initiating pi, or partnering pi.  investigators are discouraged from being named on multiple pre-applications unless they are clearly addressing distinct research questions.
• applications must include two or more breast cancer advocates on their research team.
• clinical trials are required.

funding level 4 and funding level 4 – partnering pi option

• maximum funding of $10m for direct costs (plus indirect costs)
• maximum period of performance is 4 years

era of hope scholar award – letter of intent due march 12, 2020’

independent, non-mentored investigators within 6 years of their last training position (e.g., postdoctoral fellowship, medical residency, clinical fellowship) as of the application submission deadline

• supports exceptionally talented, early-career scientists who have demonstrated that they are the “best and brightest” in their fields through extraordinary creativity, vision, innovation, and productivity.
• pis should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention.
• pis must demonstrate experience in forming effective partnerships and collaborations and exhibit strong potential for future leadership in breast cancer.
• experience in breast cancer research is not required: however, the application must focus on breast cancer, and the pi must maintain a 50% dedication of his/her full-time professional effort during the award period to breast cancer research.
• applicants must include two or more breast cancer advocates on their research team.
• submission of a letter of intent is required prior to full application submission.
• maximum funding of $3m for direct costs (plus indirect costs)
• maximum period of performance is 4 years

innovator award – preproposal due march 13, 2020

associate professor or above (or equivalent)

• supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field.
• provides opportunity to pursue novel, visionary, high-risk ideas that will accelerate progress toward ending breast cancer.
• experience in breast cancer research is not required: however, the application must focus on breast cancer, and the pi must maintain a 50% dedication of his/her full-time professional effort during the award period to breast cancer research
• applications must two or more breast cancer advocates on their research team.
• submission of a preproposal is required; application submission is by invitation only.
  • maximum funding of $7m for direct costs (plus indirect costs)
  • maximum period of performance is 4 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the bcrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk 
301-682-5507 
help@ebrap.org

applications for the 2020 allied health kidney research grant and doctoral fellowship competition must be completed via the on-line application system proposalcentralwww.proposalcentral.com. please allow extra time to review the system before the deadline of march 01, 2020. to apply through this site, you will have to set up a profile, and then search for “kidney” under “grant opportunities” and fill out the allied health kidney research grant or the doctoral fellowship application.

 

to apply to the allied health kidney scholarship, please visit the kidney foundation of canada’s website.

 

the policies for the 2020 allied health kidney research grant and doctoral fellowship are also available on the kidney foundation of canada’s website www.kidney.ca and on the proposalcentral website www.proposalcentral.com  

please note:  the french version of the on-line application system is not available at this time.  to apply in french, all forms and policies for the 2020 competition can be found on the kidney foundation of canada’s website.